巨噬细胞移动抑制因子在系统性红斑狼疮中的研究进展  

Research Progress of Macrophage Migration Inhibitory Factor in Systemic Lupus Erythematosus

作　　者：黄宇 曲航 黄琴[2] HUANG Yu;QU Hang;HUANG Qin(The Second School of Clinical Medicine,Southern Medical University,Guangzhou 510515,China;Department of Rheumatology,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China)

机构地区：[1]南方医科大学第二临床医学院,广州510515 [2]南方医科大学南方医院风湿免疫科,广州510515

出　　处：《医学综述》2020年第3期433-437,442,共6页Medical Recapitulate

基　　金：国家自然科学基金(81801624);广东省医学科学技术研究基金项目(A2019020);南方医科大学大学生创新计划项目(201812121288)

摘　　要：系统性红斑狼疮(SLE)是一种病因未明的慢性多系统自身免疫性疾病,遗传、激素和某些环境因素均与SLE的发病有关。SLE复发和缓解交替出现,病程复杂,目前的药物治疗可减少或延缓疾病的进展和器官损害,尚无法治愈。巨噬细胞移动抑制因子(MIF)是一种具有广泛免疫调节特性的多功能蛋白质,能够通过激活巨噬细胞功能、活化淋巴细胞、促进某些细胞因子的分泌和表达等途径参与SLE的发生和发展。因此,MIF可能成为自身免疫性疾病的治疗靶点,在临床应用上具有很大的潜力,但未来仍需要更深入的研究来证实其安全性和有效性。Systemic lupus erythematosus(SLE) is a typical chronic autoimmune disease involving multiple systemic damages.It is generally considered a multifactorial disease,as a combination of genetics,hormones,environmental triggers,and other factors. SLE recurrences and remissions occur alternately,and the course of disease is complex Current medication can only reduce/delay the disease progression and organ damages,but achieves no cure.Macrophage migration inhibitory factor(MIF) is a multifunctional protein with a broad range of immunomodulatory properties,which participates in the deve-lopment of SLE mainly by activating macrophage and lymphocytes,and promoting the secretion and expression of certain cytokines .Therefore,MIF may become one therapeutic target for the autoimmune disease and has a great potential in the clinical application,though larger studies are still needed to confirm the safety and efficacy in the future.

关 键 词：系统性红斑狼疮 巨噬细胞移动抑制因子 基因多态性 免疫 

分 类 号：R593[医药卫生—内科学]